Synergy Pharmaceuticals Inc., (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is engaged in the field of human therapeutics. The Company’s products include plecanatide, SP-333 and FV-100. Plecanatide is a guanylate cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is also developing SP-333, a second generation GC-C receptor agonist for the treatment of inflammatory bowel diseases, such as ulcerative colitis (UC). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for ulcerative colitis (UC), an inflammatory bowel disease. The Company’s subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.